| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Urolithin M7 targets multiple signaling pathways involved in inflammation and cell survival. It has been shown to inhibit the NF-kappaB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) pathway, a key regulator of inflammatory responses. By suppressing the phosphorylation of IkappaBalpha and the nuclear translocation of p65, Urolithin M7 reduces the expression of pro-inflammatory cytokines (TNF-alpha, IL-6). It also exhibits activity against the PI3K/AKT and MAPK pathways. Furthermore, it can induce mitophagy (via activation of PINK1/Parkin pathways). Its multi-targeted activity makes it a compound of interest for research into Alzheimer's disease, diabetes, and metabolic syndrome.
|
|---|---|
| ln Vitro |
In vitro, Urolithin M7 exhibits significant anti-inflammatory and anti-proliferative activity. In LPS-stimulated RAW264.7 macrophages, pretreatment with Urolithin M7 (1-25 uM) suppresses nitric oxide (NO) production (IC50 ~5-10 uM) and reduces the secretion of TNF-alpha and IL-6 (by ELISA). In cancer cell lines (e.g., HT-29 colon cancer, MCF-7 breast cancer), Urolithin M7 (10-50 uM) inhibits cell proliferation (MTT assay) and induces apoptosis (increased cleaved caspase-3) within 48-72 hours. It also scavenges free radicals in DPPH and ABTS assays (IC50 ~10-30 uM), demonstrating antioxidant activity. These effects are generally not observed in normal cells at low concentrations.
|
| ln Vivo |
In vivo, Urolithin M7 has demonstrated protective effects in mouse models of colitis and neuroinflammation. In a DSS (dextran sulfate sodium)-induced colitis model, oral administration of Urolithin M7 (50 mg/kg/day for 7 days) reduces the disease activity index (DAI), prevents colon shortening, and reduces colonic MPO (myeloperoxidase) activity. In a scopolamine-induced Alzheimer's model, administration of Urolithin M7 (25 mg/kg, oral) for 14 days improves cognitive function (Morris water maze) and reduces brain oxidative stress (malondialdehyde, MDA). No acute toxicity was observed at these doses.
|
| Enzyme Assay |
General protocol for in vitro enzyme/receptor binding (non-cellular): For NF-kappaB pathway inhibition, perform an ELISA-based NF-kappaB p65 transcription factor assay. Incubate nuclear extracts from LPS-stimulated cells with 5 uM of Urolithin M7. Use an ELISA plate coated with a p65-specific oligonucleotide to measure the binding activity. Urolithin M7 should reduce the OD450 reading compared to the LPS-only control. For free radical scavenging (DPPH), mix 100 uL of 100 uM DPPH (in ethanol) with 100 uL of Urolithin M7 (1-100 uM). Incubate for 30 min in the dark and measure OD517. The % scavenging = (1 - Asample/Acontrol) x 100.
|
| Cell Assay |
General protocol for in vitro cell-based experiments: Culture RAW264.7 macrophages in DMEM + 10% FBS. Seed in 96-well plates (2×10⁴ cells/well). Pre-treat with Urolithin M7 (1-25 uM) for 2 h. Stimulate with LPS (1 ug/mL) for 24 h. Collect supernatant for NO (Griess reagent) and TNF-alpha (ELISA). For viability, treat cells with Urolithin M7 (10-100 uM) for 48 h and perform MTT assay (IC50 > 50 uM in macrophages). For apoptosis, treat HT-29 cells with 50 uM compound for 48 h, stain with Annexin V-FITC/PI, and analyze by flow cytometry.
|
| Animal Protocol |
General protocol for in vivo animal experiments: For the DSS-induced colitis model, use 8-week-old male C57BL/6J mice. Administer 3% DSS in drinking water for 7 days. Treat mice with Urolithin M7 (25, 50 mg/kg) by oral gavage daily from day 0 to day 7. Euthanize on day 8. Measure colon length. Excise colon for histological scoring (H&E) and for MPO activity assay. For the Alzheimer's model, administer scopolamine (1 mg/kg, IP) daily for 14 days to induce cognitive deficits. Co-administer Urolithin M7 (25 mg/kg, PO) daily. Perform the Morris water maze test on day 12-14. Harvest brain tissue on day 15 for biochemical assays (MDA, GSH).
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: Urolithin M7 has a molecular weight of around 300-320 g/mol, depending on hydroxylation. It is a highly polar, low-molecular-weight phenolic compound (LogP ~1-2). After oral administration, it is rapidly absorbed and reaches peak plasma concentrations (Cmax) within 1-2 hours. It undergoes extensive glucuronidation and sulfation (phase II metabolism). The plasma half-life (t1/2) in rodents is approximately 2-4 hours. It is distributed to various tissues, including the brain. It is primarily excreted in urine as glucuronide/sulfate conjugates. Oral bioavailability is moderate (20-40%).
|
| Toxicity/Toxicokinetics |
General toxicity profile: Urolithin M7 is a natural metabolite and is generally considered safe (GRAS) for research purposes at moderate doses. In vitro, it is not toxic to normal cells (e.g., fibroblasts) at concentrations up to 50 uM. In acute toxicity studies, oral administration of up to 1000 mg/kg in mice causes no mortality. No significant hepatotoxicity (ALT/AST elevation) or nephrotoxicity (BUN/creatinine) is observed at therapeutic doses. However, as a polyphenol, high doses may cause mild gastrointestinal irritation. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Urolithin M7 is a gut-derived microbial metabolite of ellagic acid. Unlike its parent compounds (ellagitannins, which are poorly absorbed), urolithins are highly bioavailable. It is a research compound with promising applications in inflammatory bowel disease (IBD), diabetes, and neurodegenerative disease models. It is considered a "postbiotic" with multiple health benefits. For research use only.
|
| Molecular Formula |
C13H8O5
|
|---|---|
| Molecular Weight |
244.20
|
| CAS # |
531512-26-2
|
| Appearance |
Light brown to brown solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~4.17 mg/mL (~17.08 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
